和黄医药：2024H1呋喹替尼海外销售1.3亿美元，带动肿瘤业务收入+59%

研究报告 Research Report 1 Aug 2024 和黄医药 Hutchmed (China) Limited (13 HK) 2024H1 呋喹替尼海外销售 1.3 亿美元，带动肿瘤业务收入+59% FRUZAQLA Achieved US Market Sales of 130.5 million USD, Driving Oncology Product Revenue +59% [Table_yemei 观点聚焦 1] Investment Focus | --- | |-------------------------------------------------------------| | [Table_Info] 维持优于大市 | | 评级 | | 现价 | | 目标价 | | HTI ESG | | E-S-G: 0-5, (Please refer to the Appendix for ESG comments) | | --- | --- | |-----------------------|------------------------| | 市值 | HK$25.6 ...